Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $9.03M rose 1733.8% year over year, ahead of the +350.1% change in trailing-twelve-month financing cash flow. Sequentially, it rose 62.8% from the prior quarter.
Context
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1733.8% holds above the trailing-twelve-month pace of +350.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 12M USD
- Year-over-year change
- +174.6%
- 4-year CAGR
- +43.4%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12M | +174.6% |
| FY2024 | 2024-12-31 | 4.37M | — |
| FY2023 | 2023-12-31 | 0 | +100.0% |
| FY2022 | 2022-12-31 | (7.54M) | -365.8% |
| FY2021 | 2021-12-31 | 2.84M | — |
Financing Cash Flow vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +350.1% is the highest of 7, against a peer median of +52.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $107.35M USD | — | +221.5% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $57.15M USD | +156.6% | +136.4% | 477.0% |
| LTM Mar 2026 | $38.95M USD | -57.9% | — | 519.7% | |
| LTM Mar 2026 | $35.04M USD | +172.3% | +87.5% | — | |
| LTM Mar 2026 | $32.01M USD | -71.3% | +8.6% | 25.8% | |
| LTM Mar 2026 | $27.62M USD | — | +7.0% | — | |
| LTM Mar 2026 | CA$23.71M CAD | +114.9% | +16.7% | — | |
| LTM Mar 2026 | $20.54M USD | +350.1% | — | — | |
| LTM Mar 2026 | $11.67M USD | -10.2% | — | 77.6% | |
| Peer median (excluding GLSI) | — | +52.4% | +52.1% | 277.3% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.57M) | (7.83M) | (8.89M) | (15.79M) | (19.36M) |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| Deferred Income Tax | (1.19M) | (1.75M) | 0 | 0 | 0 |
| Stock-Based Compensation | 660.58K | 1.74M | 2.38M | 7.25M | 6.8M |
| Change in Working Capital | (385.17K) | (122.27K) | 31.5K | 1.27M | 2.64M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (526.73K) | 0 | 35.47K | 921.22K | 2.07M |
| Other Working Capital | 141.57K | (122.27K) | (3.97K) | 344.11K | 568.12K |
| Other Non-Cash Items | 1.19M | 1.75M | 0 | 0 | 0 |
| Operating Cash Flow | (4.29M) | (6.2M) | (6.48M) | (7.27M) | (9.91M) |
| Capital Expenditures | 0 | (3) | 0 | 3 | 3 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 3.11M | 0 | 0 | 4.37M | 12M |
| Common Stock Repurchased | 0 | (7.54M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (275.15K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 2.84M | (7.54M) | 0 | 4.37M | 12M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.46M) | (13.74M) | (6.48M) | (2.9M) | 2.09M |
| Free Cash Flow | (4.29M) | (6.2M) | (6.48M) | (7.27M) | (9.91M) |
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.